Medical Research Group of Egypt, Cairo, Egypt.
Faculty of Medicine, School of Medicine, Zagazig University, Sharkia, Zagazig, 44523, Egypt.
Neurol Sci. 2021 Aug;42(8):3135-3143. doi: 10.1007/s10072-021-05319-7. Epub 2021 May 20.
Mavoglurant (AFQ056), a selective metabotropic glutamate receptor 5 (mGluR5) inhibitor, was tested for t levodopa-induced dyskinesia (LID) in patients with Parkinson's Disease (PD). However, clinical trials showed inconsistent results regarding the efficacy of mavoglurant in treating LID in patients with Parkinson's disease (PD).
A computer literature search of PubMed, Scopus, Web of science, and Cochrane CENTRAL was conducted until March 2021. We selected relevant randomized controlled trials comparing mavoglurant to placebo. Study data were extracted and pooled as mean difference (MD) in the meta-analysis model.
Six RCTs were included in this meta-analysis with a total of 485 patients. Mavoglurant was not significantly superior to placebo in terms of the "off-time" (MD -0.27 h, 95% CI -0.65 to 0.11), "on time" (MD 0.29 h, 95% CI -0.09 to 0.66), Lang-Fahn activities of daily living dyskinesia scale (MD -0.95, 95% CI -1.98 to 0.07), UPDRS-III (MD -0.51, 95% CI -1.66 to 0.65), or UPDRS-IV (MD -0.41, 95% CI -0.85 to 0.03). However, the pooled modified abnormal involuntary movement scale favored the mavoglurant group than the placebo group (MD -2.53, 95% CI -4.23 to -0.82).
This meta-analysis provides level one evidence that mavoglurant is not effective in treating the LID in patients with PD.
莫瓦格鲁单抗（AFQ056）是一种选择性代谢型谷氨酸受体 5（mGluR5）抑制剂，已在帕金森病（PD）患者中进行了左旋多巴诱导的运动障碍（LID）的测试。然而，临床试验显示莫瓦格鲁单抗治疗帕金森病（PD）患者 LID 的疗效不一致。
计算机检索PubMed、Scopus、Web of Science 和 Cochrane CENTRAL，检索时限均为 2021 年 3 月前。我们选择了比较莫瓦格鲁单抗与安慰剂的相关随机对照试验。提取研究数据，并在荟萃分析模型中汇总为均数差（MD）。
本荟萃分析纳入了 6 项 RCT，共 485 例患者。莫瓦格鲁单抗在“关期”（MD-0.27 h，95%CI-0.65 至 0.11）、“开期”（MD 0.29 h，95%CI-0.09 至 0.66）、Lang-Fahn 日常生活活动障碍量表（MD-0.95，95%CI-1.98 至 0.07）、UPDRS-III（MD-0.51，95%CI-1.66 至 0.65）或 UPDRS-IV（MD-0.41，95%CI-0.85 至 0.03）方面均无明显优于安慰剂。然而，汇总的改良异常不自主运动量表显示莫瓦格鲁单抗组优于安慰剂组（MD-2.53，95%CI-4.23 至-0.82）。
本荟萃分析提供了一级证据，表明莫瓦格鲁单抗治疗 PD 患者的 LID 无效。
